Institute for Regenerative Medicine, University of Zurich, Campus Schlieren, Wagistrasse 12, 8952, Zurich, Schlieren, Switzerland.
Department of Health Sciences and Technology, ETH Zürich, 8093, Zurich, Switzerland.
Alzheimers Res Ther. 2024 Apr 1;16(1):67. doi: 10.1186/s13195-024-01435-6.
White matter hyperintensities (WMHs) are often measured globally, but spatial patterns of WMHs could underlie different risk factors and neuropathological and clinical correlates. We investigated the spatial heterogeneity of WMHs and their association with comorbidities, Alzheimer's disease (AD) risk factors, and cognition.
In this cross-sectional study, we studied 171 cognitively unimpaired (CU; median age: 65 years, range: 50 to 89) and 51 mildly cognitively impaired (MCI; median age: 72, range: 53 to 89) individuals with available amyloid (18F-flutementamol) PET and FLAIR-weighted images. Comorbidities were assessed using the Cumulative Illness Rating Scale (CIRS). Each participant's white matter was segmented into 38 parcels, and WMH volume was calculated in each parcel. Correlated principal component analysis was applied to the parceled WMH data to determine patterns of WMH covariation. Adjusted and unadjusted linear regression models were used to investigate associations of component scores with comorbidities and AD-related factors. Using multiple linear regression, we tested whether WMH component scores predicted cognitive performance.
Principal component analysis identified four WMH components that broadly describe FLAIR signal hyperintensities in posterior, periventricular, and deep white matter regions, as well as basal ganglia and thalamic structures. In CU individuals, hypertension was associated with all patterns except the periventricular component. MCI individuals showed more diverse associations. The posterior and deep components were associated with renal disorders, the periventricular component was associated with increased amyloid, and the subcortical gray matter structures was associated with sleep disorders, endocrine/metabolic disorders, and increased amyloid. In the combined sample (CU + MCI), the main effects of WMH components were not associated with cognition but predicted poorer episodic memory performance in the presence of increased amyloid. No interaction between hypertension and the number of comorbidities on component scores was observed.
Our study underscores the significance of understanding the regional distribution patterns of WMHs and the valuable insights that risk factors can offer regarding their underlying causes. Moreover, patterns of hyperintensities in periventricular regions and deep gray matter structures may have more pronounced cognitive implications, especially when amyloid pathology is also present.
脑白质高信号(WMH)通常进行整体测量,但WMH 的空间模式可能与不同的风险因素、神经病理学和临床相关因素有关。我们研究了 WMH 的空间异质性及其与共病、阿尔茨海默病(AD)危险因素和认知的关系。
在这项横断面研究中,我们研究了 171 名认知正常(CU;中位年龄:65 岁,范围:50 至 89 岁)和 51 名轻度认知障碍(MCI;中位年龄:72 岁,范围:53 岁至 89 岁)个体,这些个体均有可用的淀粉样蛋白(18F-flutemetamol)PET 和 FLAIR 加权图像。使用累积疾病评分量表(CIRS)评估共病。将每个参与者的脑白质分为 38 个区,计算每个区的 WMH 体积。应用相关主成分分析确定 WMH 数据的变化模式。使用调整和未调整的线性回归模型研究成分评分与共病和 AD 相关因素的关系。使用多元线性回归,我们测试了 WMH 成分评分是否可以预测认知表现。
主成分分析确定了四个 WMH 成分,这些成分广泛描述了后部、脑室周围和深部脑白质区域以及基底节和丘脑结构的 FLAIR 信号高信号。在 CU 个体中,高血压与除脑室周围成分之外的所有模式相关。MCI 个体表现出更多样的关联。后部和深部成分与肾脏疾病相关,脑室周围成分与淀粉样蛋白增加相关,皮质下灰质结构与睡眠障碍、内分泌/代谢障碍和淀粉样蛋白增加相关。在合并样本(CU+MCI)中,WMH 成分的主要效应与认知无关,但在存在淀粉样蛋白增加的情况下,预测了较差的情景记忆表现。未观察到高血压与共病数量对成分评分的交互作用。
我们的研究强调了理解 WMH 区域分布模式的重要性,以及风险因素为了解其潜在原因提供的有价值的见解。此外,脑室周围区域和深部灰质结构的高信号模式可能具有更明显的认知意义,尤其是当淀粉样蛋白病理存在时。